Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL16893970 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL14637050 | 1.00 | — | — | |
| Valine SCHEMBL16893971 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL3426769 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL132740 | 1.00 | — | — | |
| Valine SCHEMBL23777447 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL3402665 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL10775583 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL9439900 | 1.00 | SLC7A5 (0.94) | — | |
| Valine SCHEMBL351273 | 0.97 | SLC7A5 (0.88) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708368-B2 | Crystal form of ethyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate hydrochloride | JIANGSU NHWALUOKANG PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2023-07-25 | — | — | US | claimed |
| US-20210002283-A1 | Benzodiazepine Derivative Hydrochloride and Crystal Form, Preparation Method and Application thereof | JIANGSU NHWALUOKANG PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2021-01-07 | — | — | US | claimed |
| EP-3753940-A1 | BENZODIAZEPINE DERIVATIVE HYDROCHLORIDE AND CRYSTAL FORM, PREPARATION METHOD, AND APPLICATION THEREOF | Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. (CN) | 2020-12-23 | — | — | EP | claimed |
| CN-111712501-A | Benzodiazepine derivative hydrochloride, crystal form, preparation method and application thereof | 江苏恩华络康药物研发有限公司 | 2020-09-25 | — | — | CN | claimed |
| EP-3082778-B1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2019-04-03 | — | — | EP | claimed |
| EP-3436021-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RespireRx Pharmaceuticals Inc. (US) | 2019-02-06 | — | — | EP | claimed |
| CN-108440626-A | The crystal form and preparation method thereof of 5 '-O-L- valinate hydrochlorides of cytarabine | 昆明积大制药股份有限公司 | 2018-08-24 | — | — | CN | claimed |
| WO-2018009256-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RESPIRERX PHARMACEUTICALS, INC. (US) | 2018-01-11 | — | — | WO | claimed |
| CN-106242985-A | Synthesis method and application of chiral L-valine hydrochloride crystal | 合肥祥晨化工有限公司 | 2016-12-21 | — | — | CN | claimed |
| EP-3008062-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | claimed |
| EP-0877746-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-18 | — | — | EP | claimed |
| WO-1997027195-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | claimed |
| US-5480574-A | 2-aminocarboxylic acid hydrochloride compositions for removal of hard-water deposits | SINGERMAN GARY M (US) | 1996-01-02 | — | — | US | claimed |
| EP-0554422-B1 | USE OF DL-VALIN, ITS ESTERS AND/OR ITS SALTS IN THE TREATMENT OF DANDRUFF | WELLA AG (DE) | 1995-08-30 | — | — | EP | claimed |
| EP-0468929-B1 | Stabilized pharmaceutical compositions | SANDOZ LTD (CH) | 1994-09-28 | — | — | EP | claimed |
| EP-0610466-A1 | USE OF DL-VALIN, ITS ESTERS AND/OR SALTS TO CONTROL THE GREASY APPEARANCE OF HAIR OR SKIN | Wella Aktiengesellschaft (DE) | 1994-08-17 | — | — | EP | claimed |
| WO-1994003145-A1 | USE OF DL-VALIN, ITS ESTERS AND/OR SALTS TO CONTROL THE GREASY APPEARANCE OF HAIR OR SKIN | WELLA AKTIENGESELLSCHAFT (DE) | 1994-02-17 | — | — | WO | claimed |
| EP-0554422-A1 | USE OF DL-VALIN, ITS ESTERS AND/OR ITS SALTS IN THE TREATMENT OF DANDRUFF. | WELLA AG (DE) | 1993-08-11 | — | — | EP | claimed |
| WO-1993004661-A1 | USE OF DL-VALIN, ITS ESTERS AND/OR ITS SALTS IN THE TREATMENT OF DANDRUFF | WELLA AKTIENGESELLSCHAFT (DE) | 1993-03-18 | — | — | WO | claimed |
| EP-0468929-A2 | Stabilized pharmaceutical compositions | SANDOZ LTD. (CH) | 1992-01-29 | — | — | EP | claimed |